Abstract
Repeat expansions in the FGF14 gene have recently been identified as a frequent cause of autosomal dominant late-onset cerebellar ataxia (SCA27B). The threshold for pathogenicity was estimated to range from 250 (incomplete penetrance) to 300 AAG repeats (full penetrance) based on expansion sizes observed in patients and controls. However, the full sequences of pathogenic and non-pathogenic alleles remain largely unknown.
In this study, we used STRling and ExpansionHunter/STRipy to detect short tandem repeat expansions in short-read genome data of 80 patients with unsolved neurological disorders, including 48 patients from 39 unrelated families with cerebellar ataxia. Significant outlier values indicating a possible FGF14 repeat expansion were detected in 49% of families with ataxia. We used long-range PCR and repeat-primed PCR to confirm repeat motifs and number, and to further screen for FGF14 repeat expansions in 106 additional patients. The distribution of FGF14 alleles was also analyzed in 802 control individuals. Long-range PCR amplicons from affected and control subjects with at least one expanded allele were sequenced by nanopore sequencing.
Altogether, we report a total of 38 individuals from 31 families with a pure AAG expansion ≥250 repeats in FGF14 (range: 254-937) out of 134 families with unsolved ataxia (23%). Four families had biallelic expansions. One individual showed mosaicism of the expansion, with two distinct large alleles detected. The overall distribution of FGF14 alleles significantly differs in patients and control subjects with pure expansions from 180 repeats being enriched in patients while AAGGAG and interrupted alleles were more frequent in controls. Expanded and non-expanded FGF14 alleles were associated with different 5’-flanking regions correlating with repeat stability. Episodic symptoms of ataxia and downbeat nystagmus were frequent in patients with SCA27B independently of the repeat number. A family with a novel nonsense variant (NM_175929.3: c.239T>G; p.Leu80*; SCA27A) exhibited similar symptoms but earlier age at onset than patients with pathogenic expansions (SCA27B).
In conclusion, this study reveals the complete sequence of pathogenic and non-pathogenic FGF14 expansions. We suggest that pure AAG expansions are pathogenic from a lower threshold than previously reported, comprised between 180 and 220 pure AAG repeats, while full penetrance would be above 320-335 repeats. Interrupted expansions and expansions composed of other hexanucleotide repeats motifs are non-pathogenic. Diagnostic tests should thus include a complete sequencing of the expansion in addition to repeat number assessment. Finally, we provide mechanistic insights into how pure AAG repeat expansions could lead to adult-onset cerebellar ataxia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Tom Wahlig foundation, the University Hospital Essen, and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Research Infrastructure West German Genome Center (project 407493903) as part of the Next Generation Sequencing Competence Network (project 423957469). Short-read genome sequencing was carried out at the production site Cologne (Cologne Center for Genomics; CCG). C.D. received the DFG 458099954 as part of the DFG Sequencing call #3. S.Kl. was supported by the German Federal Ministry of Education and Research (BMBF) through the TreatHSP consortium (01GM1905C). M.S. and -as an associated partner- D.T. and S. Kl. were also supported by the DFG (grant number 441409627), as part of the PROSPAX consortium under the frame of European Joint Programme on Rare Diseases (EJP-RD), under the EJP RD COFUND-EJP N° 825575. J.P. was supported by the Clinician Scientist program "PRECISE.net" funded by the Else Kröner-Fresenius-Stiftung. F.J.K. received funding from the DFG Research Unit FOR2488. Genome sequencing in Spanish patients was supported by the Undiagnosed Rare Diseases Program of Catalonia (URDCat; PERIS SLT002/16/00174) from the Autonomous Government of Catalonia; the Biomedical Research Networking Center on Rare Diseases (CIBERER, ACCI19-759); the Hesperia Foundation (Royal House of Spain), and "La Marató de TV3" Foundation with project 202006-30 to C.C. and A.P. and the Instituto de Salud Carlos III co-funded by the "Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, una manera de hacer Europa" (FIS PI20/00758) to C.C., and IMPACT-Genomica (IMP/00009) to A.P.. M.R. was funded by the Center for Biomedical Research on Rare Diseases, an initiative of the Instituto de Salud Carlos III. We thank the CERCA Program/Generalitat de Catalunya for institutional support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of University Hospital Essen gave ethical approval for this work (21-10155-BO).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data and scripts included in this study, with the exception of genome data, are available from the Supplementary tables or in the Github repository.
